|1.||Fukushima, Shinji: 4 articles (12/2004 - 08/2002)|
|2.||Kokubo, Satoshi: 3 articles (09/2004 - 08/2002)|
|3.||Teramura, Kyoko: 3 articles (09/2004 - 08/2002)|
|4.||Nozaki, Kazutoshi: 3 articles (09/2004 - 08/2002)|
|5.||Takahashi, Koichiro: 3 articles (09/2004 - 08/2002)|
|6.||Shuto, Toshihide: 2 articles (06/2006 - 06/2003)|
|7.||Zhao, Hongpu: 2 articles (06/2006 - 06/2003)|
|8.||Iwamoto, Yukihide: 2 articles (06/2006 - 06/2003)|
|9.||Kohri, Kenjiro: 2 articles (01/2006 - 06/2004)|
|10.||Iwai, Takaya: 2 articles (12/2004 - 12/2002)|
|1.||Neoplasm Metastasis (Metastasis)
02/01/2002 - "Bone scan with 99mTc-labeled incadronate (99mTc-incadronate) may yield important information prior to the use of incadronate for treatment of bone metastases. "
05/01/1997 - "5. These results strongly suggest that pharmacological action of incadronate in mouse with bone metastases (inhibitory effect on the growth of metastatic tumour in bone) is caused not by the direct action on the tumour cells but by the distribution of the drug in the perifocal bone region followed by inhibition of the activity of osteoclasts, resulting in inhibition of the osteolytic process, which is necessary for the progress of metastatic tumour."
05/01/1997 - "2. The pharmacokinetics of incadronate (plasma concentration, urinary excretion and bone uptake) in rat with bone metastases was not markedly different from that in the control rat. "
05/01/1997 - "Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases."
02/01/2002 - "We first labeled incadronate disodium with 99mTc, and examined its biodistribution and bone uptake after intravenous injection in rats to assess its potential for clinical use as a bone-seeking agent for judgment of the therapeutic effect of incadronate on bone metastases. "
|2.||Breast Neoplasms (Breast Cancer)
10/01/1999 - "To assess the safety of rapid infusion of incadronate and its efficacy against bone metastasis of breast cancer, we conducted a trial using incadronate therapy for breast cancer patients with bone metastasis. "
10/01/1999 - "[Study on the safety of rapid infusion and the efficacy of incadronate against bone metastasis of breast cancer]."
10/01/1999 - "In conclusion, rapid infusion of incadronate was a safe treatment and the incadronate therapy was effective against bone metastasis of breast cancer."
09/01/1999 - "We examined the effects of a third generation bisphosphonate, YM175, in a nude mice jaw metastasis model with intracardiac injection of a human breast cancer cell line, MDA-MB-231. "
08/01/2000 - "Bisphosphonate therapy of sequential pamidronate and incadronate with MPA administration is a useful treatment for bone metastasis from breast cancer."
|3.||Hypercalcemia (Milk Alkali Syndrome)
05/01/2007 - "Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study."
06/01/1997 - "Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia."
06/01/1997 - "We investigated the pharmacokinetics of incadronate, a new bisphosphonate, after a 2-hour intravenous infusion to healthy volunteers and patients with malignancy-associated hypercalcemia. "
02/01/1998 - "These results indicated that YM175 is expected to be a useful drug for hypercalcemia associated with malignant tumors due to its efficacy and range of effect."
02/01/1998 - "Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats."
05/01/2003 - "The purpose of this study was to investigate the effect of incadronate in preventing periodontal destruction in rats with Porphyromonas gingivalis-induced periodontitis. "
05/01/1998 - "Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs."
05/01/1998 - "This study examined the efficacy of YM175 [disodium dihydrogen (cycloheptylamino) methylene-1, 1-bisphosphonate] in reducing alveolar bone loss caused by experimental periodontitis in beagle dogs. "
05/01/2003 - "Inhibitory effects of incadronate on the progression of rat experimental periodontitis by porphyromonas gingivalis infection."
05/01/1998 - "These results suggest that YM175 prevents alveolar bone loss by reducing the increased alveolar bone turnover in dogs with periodontitis."
01/01/2000 - "This study provides the first evidence that YM175, among aminobisphosphonates, not only inhibits bone destruction in rat AA, probably by reducing osteoclast numbers, but that it also suppresses joint inflammation. "
06/01/2003 - "The mechanism underlying these antiinflammatory actions of incadronate may be attributable to the inhibition of macrophage migration to the site of inflammation. "
06/01/2003 - "Incadronate not only inhibits bone destruction but also reduces cartilage degeneration and joint inflammation in rats with established AIA. "
06/01/2006 - "The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis."
01/01/2000 - "These results suggest that YM175 may be a useful drug for the prophylactic treatment of both bone destruction and joint inflammation in patients with rheumatoid arthritis."
|7.||zoledronic acid (zoledronate)
|10.||Interleukin-1beta (Interleukin 1 beta)